AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11595472
Drug: RBC-C (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBC-C (2 x 400 mg ranitidin bismuth citrate + 2 x 500 mg clarithromycin for 14 days)
Trial: 11595472
Drug: LCM (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCM (2 x 30 mg lansoprazole + 2 x 250 mg clarithromycin + 2 x 500 mg metronidazole)
Trial: 11595472
Drug: RBC-CM (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBC-CM (2 x 400 mg ranitidin bismuth citrate + 2 x 250 mg clarithromycin + 2 x 500 mg metronidazole)
Trial: 9402342
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with three drugs
Trial: 9402342
Drug: Antibodies to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibodies to VacA
Trial: 9402342
Drug: Antibodies to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibodies to CagA
Trial: 8428859
Drug: Oral route
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral route (OR)
Trial: 3313099
Drug: L-baclofen
RxNorm normalized name: L-Baclofen
DrugBank: L-Baclofen (DB12098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-baclofen
Trial: 29691197
Drug: Standard Medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Medication Counseling (SMC)
Trial: 27006332
Drug: Enzalutamide (160mg)
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide (160mg) once daily
Trial: 24941010
Drug: Combined administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined administration of insulin and glucose, titrated to preserve normoglycemia (3.5‐6.1 mmol L(‐1))
Trial: 24941010
Drug: Standard metabolic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard metabolic care (blood glucose 3.5‐10 mmol L(‐1))
Trial: 21575130
Drug: N7-GP (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N7-GP (dose of 12.5-100 μg kg(‐1))
Trial: 12946546
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium 2.0% ophthalmic solution
Trial: 8403154
Drug: 2-Chloroprocaine 100
RxNorm normalized name: 2-chloroprocaine
DrugBank: Chloroprocaine (DB01161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2-Chloroprocaine 100 mg
Trial: 3437302
Drug: Clonazepam (0.5-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonazepam (0.5-2 mg per night)
Trial: 29206813
Drug: Baclofen (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen (10 mg, t.i.d)
Trial: 27881136
Drug: CHWs prescribed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHWs prescribed artemisinin-based combination therapy (ACT)
Trial: 31864376
Drug: Pre-referral treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-referral treatment with rectal artesunate
Trial: 1632534
Drug: Ketorolac (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac (60 mg)
Trial: 7893296
Drug: Meperidine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine (75 mg)/Promethazine (25 mg)
Trial: 30077530
Drug: Intensive PD
RxNorm normalized name: Dianeal PD-2/2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive PD treatment (IPT)
Trial: 30077530
Drug: Standard PD
RxNorm normalized name: PD-0299685
DrugBank: PD-0299685 (DB15264)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard PD treatment (CPT)
Trial: 18498915
Drug: Valsartan/HCTZ combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan/HCTZ combination therapy
Trial: 22410289
Drug: Valsartan monotherapy
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Valsartan monotherapy
Trial: 15948086
Drug: Scheduled telephone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scheduled telephone calls by specially trained nurses promoting self‐management and guideline‐based therapy
Trial: 12013192
Drug: d-alpha-tocopherol 1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-alpha-tocopherol 1,200 I.U. daily
Trial: 12013192
Drug: ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ascorbic acid 2 g daily
Trial: 12013192
Drug: ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ascorbic acid 2 g plus d-alpha-tocopherol 1,200 I.U. daily
Trial: 7772663
Drug: Propofol 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 1.5 mg/kg followed by continuous infusion of 6 mg/kg/h, and alfentanil 15 micrograms/kg followed by continuous infusion of 15 micrograms/kg/h
Trial: 444406
Drug: Chemotherapy (cyclophosphamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (cyclophosphamide, vincristine, adriamycin and 5‐fluorouracil)
Trial: 444406
Drug: Hormonal therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal therapy (oophorectomy, tamoxifen or androgens)
Trial: 444406
Drug: Other tests
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other tests (phytohaemagglutinin response, immunoglobulins G, A and M, or Mantoux test)
Trial: 28052931
Drug: L.A.D.I.E.S. intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L.A.D.I.E.S. intervention
Trial: 20875219
Drug: Quetiapine-XR ≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine-XR ≥ 300 mg/d
Trial: 20875219
Drug: Quetiapine-XR (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine-XR (600 mg/d and 800 mg/d)
Trial: 9692075
Drug: HRT (estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT (estradiol valerate (2 mg) plus cyproterone acetate, 1 mg, sequentially: ClimenR)
Trial: 9692075
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (16 women who refused all treatment)
Trial: 7925172
Drug: Vigabatrin (gamma‐vinyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigabatrin (gamma‐vinyl GABA; VGB) as add-on therapy
Trial: 3294079
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (sham-bubble)
Trial: 28444396
Drug: CPAP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP treatment for at least 3 months
Trial: 28444396
Drug: SDB patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDB patients (no CPAP treatment)
Trial: 14967873
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (20 g x d(‐1) Cr + 140 g x d(‐1) glucose for 7 days, followed by 5 g x d(‐1) Cr + 35 g x d(‐1) glucose for 21 days)
Trial: 14967873
Drug: Placebo (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (160 g x d(‐1) glucose [loading] followed by 40 g x d(‐1) [maintenance])
Trial: 11092065
Drug: Bromocriptine 2.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine 2.50 mg
Trial: 11092065
Drug: Bromocriptine 3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine 3.75 mg
Trial: 1519828
Drug: Budesonide 0.8
RxNorm normalized name: DIAZOLIDINYL UREA 446 ug in 48 h / CLIOQUINOL 77 ug in 48 h / CHLORQUINALDOL 77 ug in 48 h / TIXOCORTOL PIVALATE 2 ug in 48 h / GOLD SODIUM THIOSULFATE 23 ug in 48 h / IMIDUREA 486 ug in 48 h / BUDESONIDE 0.8 ug in 48 h / HYDROCORTISONE BUTYRATE 16 ug in 48 h / 2-MERCAPTOBENZOTHIAZOLE 61 ug in 48 h / BACITRACIN 486 ug in 48 h / PARTHENOLIDE 2 ug in 48 h / DISPERSE BLUE 106 41 ug in 48 h / BRONOPOL 203 ug in 48 h CUTANEOUS PATCH [T.R.U.E. Test Panel 3.3]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 0.8 mg twice daily for 14 days
Trial: 6832199
Drug: Prajmalium bitartrate
RxNorm normalized name: prajmalium bitartrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prajmalium bitartrate (PB) 80 mg/day for 4 days
Trial: 6832199
Drug: Disopyramide 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disopyramide 400 mg/day for 4 days
Trial: 30454846
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsule and gabapentin 900mg
Trial: 16087941
Drug: Induction paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Induction paclitaxel (200 mg/m2)/carboplatin (AUC = 6) followed by TRT 63.0 Gy (arm 1, sequential)
Trial: 16087941
Drug: Induction paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Induction paclitaxel (200 mg/m2)/carboplatin (AUC = 6) followed by weekly paclitaxel (45 mg/m2)/carboplatin (AUC = 2) with concurrent TRT 63.0 Gy (arm 2, induction/concurrent)
Trial: 16087941
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel (45 mg/m2)/carboplatin (AUC = 2)/TRT (63.0 Gy) followed by two cycles of paclitaxel (200 mg/m2)/carboplatin (AUC = 6; arm 3, concurrent/consolidation)
Trial: 16087941
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (arms 1 and 2)
Trial: 16087941
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy (arms 2 and 3)
Trial: 11583475
Drug: Dexamethasone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.5 mg/kg/day for the first 3 days, 0.25 mg/kg/day for the next 3 days, and 0.125 mg/kg/day for the 7th day)
Trial: 9826308
Drug: Bosentan 200
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bosentan 200 mg IV
Trial: 7926327
Drug: Selective dorsal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective dorsal rhizotomy (SDR) followed by one month of physical therapy at the center and a community physical therapy program
Trial: 2688070
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg omeprazole once daily for 2 weeks
Trial: 3512351
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg omeprazole once daily for 4 weeks
Trial: 1106934
Drug: Carbamazepine (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (1,200 mg) and Phenytoin (300 mg)
Trial: 1106934
Drug: Carbamazepine (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (1,200 mg) and Phenobarbital (300 mg)
Trial: 1106934
Drug: Phenytoin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenytoin (300 mg) and Phenobarbital (300 mg)
Trial: 1106934
Drug: Carbamazepine (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (1,200 mg), Phenytoin (300 mg), and Phenobarbital (300 mg)
Trial: 1106934
Drug: Carbamazepine (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (1,200 mg)
Trial: 1106934
Drug: Phenytoin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenytoin (300 mg)
Trial: 1106934
Drug: Phenobarbital (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbital (300 mg)
Trial: 295704
Drug: Oral prophylaxis
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prophylaxis
Trial: 28329340
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg enteric-coated aspirin daily for 5 years
Trial: 27611093
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment (Control Group)
Trial: 15041391
Drug: Muromonab (OKT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muromonab (OKT 3) + Neoral + adjunct + standard prednisone
Trial: 15041391
Drug: Simulect +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simulect + Neoral + adjunct + steroid sparing
Trial: 15041391
Drug: Simulect +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simulect + Neoral + adjunct + no prednisone
Trial: 9738728
Drug: Montelukast (5-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (5-mg chewable tablet) once daily in the evening for 2 days
Trial: 8281660
Drug: iohexol (low-osmolality
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iohexol (low-osmolality contrast agent)
Trial: 8281660
Drug: diatrizoate (high-osmolality
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diatrizoate (high-osmolality contrast agent)
Trial: 8281660
Drug: Algorithm for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algorithm for selective use of low-osmolality agents
Trial: 15767771
Drug: 2% ketoconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% ketoconazole cream
Trial: 26067687
Drug: Metformin (escalated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (escalated from 500 mg to 1000 mg twice daily)
Trial: 21806596
Drug: Lifestyle treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle treatment
Trial: 16805713
Drug: Isolated and
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isolated and adjuvant treatment of rhinitis and asthma
Trial: 16805713
Drug: Clinical studies
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical studies regarding joint treatment
Trial: 10921561
Drug: Intravenous erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous erythromycin (200 mg)
Trial: 8609658
Drug: Chemotherapy (four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (four courses of cisplatin [20 mg/m2] and fluorouracil [200 mg/m2], given daily for 5 consecutive days during weeks 1, 4, 7, and 10) plus radiotherapy (three courses of 20 Gy each, given in fractions of 2 Gy per day during weeks 2‐3, 5‐6, and 8‐9)
Trial: 8609658
Drug: Radiotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy alone (70 Gy total dose, given in fractions of 2 Gy per day, 5 days per week)
Trial: 3906674
Drug: Piretanide (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piretanide (6 mg once daily)
Trial: 3906674
Drug: Piretanide plus
RxNorm normalized name: piretanide
DrugBank: Piretanide (DB02925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piretanide plus triamterene (6 mg + 50 mg once daily)
Trial: 29097626
Drug: Standard carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard carbohydrate content (75 g, LCD)
Trial: 29097626
Drug: Double carbohydrate
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double carbohydrate content (150 g, HCD)
Trial: 25315409
Drug: 30mg morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mg morphine hydrochloride
Trial: 24597251
Drug: Tibolone 2.5
RxNorm normalized name: tibolone 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone 2.5 mg/d for six months
Trial: 21990420
Drug: Early initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Early initiation of antiretroviral therapy (ART)
Trial: 18671167
Drug: Four types
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four types of spoken sentences presented for immediate free recall: four short simple sentences, eight short simple sentences, four compound sentences, and four random word lists.
Trial: 10622295
Drug: Infliximab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (3 mg/kg every 4 or 8 weeks)
Trial: 10622295
Drug: Infliximab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (10 mg/kg every 4 or 8 weeks)
Trial: 7572705
Drug: Carbohydrate restriction
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate restriction (84 h fasting with lipid emulsion infusion for 12-15 h each day)
Trial: 1826506
Drug: Immunization with
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunization with type 3 pneumococcal vaccine
Trial: 28640217
Drug: Total iodine
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total iodine intake (food and supplements)
Trial: 28640217
Drug: Iodine-containing supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodine-containing supplement intake
Trial: 25651491
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (lipid emulsion eye drops, omega-3 supplements, eyelid cleansing wipes)
Trial: 9834008
Drug: Current use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current use of any oral contraceptive (OC)
Trial: 9834008
Drug: Noncurrent use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noncurrent use of oral contraceptives (OC)
Trial: 9834008
Drug: Different generations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different generations of oral contraceptives
Trial: 9691922
Drug: Leu13‐motilin (KW‐5139)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leu13‐motilin (KW‐5139) infusion at doses of 2, 4, 8, and 16 pmol/kg/min
Trial: 9691922
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% NaCl) infusion
Trial: 1681680
Drug: Zuclopenthixol decanoate
RxNorm normalized name: zuclopenthixol decanoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zuclopenthixol decanoate (ZPT‐D) 100‐600 mg every 4 weeks
Trial: 1681680
Drug: Haloperidol decanoate
RxNorm normalized name: Haloperidol Decanoate
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol decanoate (HAL‐D) 38‐200 mg every 4 weeks
Trial: 28385397
Drug: L-proline supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-proline supplementation during early pregnancy
Trial: 28385397
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no L-proline supplementation)
Trial: 18054445
Drug: Hospital treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital treatment as usual without additional counselling (Control)
Trial: 12759298
Drug: Fenofibrate (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate (300 mg once daily) plus anti-hyperuricaemic agents (including benzbromarone 50 mg once daily or allopurinol 200 mg twice a day)
Trial: 12759298
Drug: Losartan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (50 mg once daily) plus anti-hyperuricaemic agents (including benzbromarone 50 mg once daily or allopurinol 200 mg twice a day)
Trial: 8815570
Drug: Fragmin (2500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fragmin (2500 IU sc once daily for 90 days)
Trial: 1945215
Drug: Hydration group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydration group (2 L of water plus usual fluid)
Trial: 27128831
Drug: Bazedoxifene 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bazedoxifene 80 mg
Trial: 27128831
Drug: Bazedoxifene (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bazedoxifene (5 mg and greater)
Trial: 27128831
Drug: Bazedoxifene (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bazedoxifene (various doses)
Trial: 27128831
Drug: Bazedoxifene (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bazedoxifene (1, 2.5, 5, 10, 20, 40, and 80 mg)
Trial: 17686444
Drug: 3- and
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3- and 4-drug regimens
Trial: 3576660
Drug: Carbamazepine tablets
RxNorm normalized name: Carbamazepine Tablets
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine tablets
Trial: 1222752
Drug: Carbamazepine syrup
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine syrup
Trial: 1222752
Drug: Carbamazepine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (both preparations)
Trial: 31175806
Drug: Flaxseed lignan
RxNorm normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed lignan supplement (50 mg secoisolariciresinol diglucoside/d)
Trial: 31175806
Drug: Flaxseed lignan
RxNorm normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed lignan supplement
Trial: 25381193
Drug: Baseline first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline first phase insulin response (FPIR) ≤3 μU/mL during IvGTT
Trial: 25381193
Drug: Maximal plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximal plasma glucose ≥11.1 mmol/L measured at 30, 60 and/or 90 min during OGTT
Trial: 25381193
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of FPIR from IvGTT and maximal plasma glucose during OGTT
Trial: 23162100
Drug: K‐citrate (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K‐citrate (60 mEq daily)
Trial: 16882343
Drug: Home UVB
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home UVB treatment
Trial: 8237086
Drug: Sitting position
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitting position with liquid bolus (5 ml water)